Application Serial No. 10/568,572 (Attorney Docket No. 453-US-PCT) Response to Non-Final Office Action mailed: May 13, 2008 Dated: November 13, 2008 Page 2 of 15

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of the Claims:**

Claims 1-46 (Cancelled)

47. (Currently amended) A <u>crystalline</u> succinate salt or a <u>crystalline</u> malonate salt of [[the]] <u>a</u> compound of formula (I)

48. (Currently amended) The <u>crystalline</u> succinate salt of claim 47, wherein the <u>succinate</u> salt is [[the]] <u>a crystalline</u> hydrogen succinate salt.

(I)

- 49. (Cancelled)
- 50. (Currently amended) The crystalline hydrogen succinate salt of claim [[49]]48, wherein the salt comprises an alpha crystal form-is-alpha.
- 51. (Currently amended) The crystalline hydrogen succinate salt of claim 50, wherein the <a href="alpha\_crystal">alpha\_crystal</a> form of the salt is characterized by an X-Ray powder diffractogram as shown in Figure 1.
- 52. (Currently amended) The crystalline hydrogen succinate salt of claim 51, wherein the X-Ray powder diffractogram, which was obtained using CuK<sub>α1</sub> radiation (λ=1.5406 Å), has characteristic showing peaks at the following 2θ-angles: 9.36; 10.23; 11.81; 13.45; 16.21;

Application Serial No. 10/568,572 (Attorney Docket No. 453-US-PCT) Response to Non-Final Office Action mailed: May 13, 2008 Dated: November 13, 2008 Page 3 of 15

- 16.57; 17.49; 18.89; 19.20; 19.63; 20.01; 20.30; 21.15; 21.53; 21.93; 22.34; 24.37; 25.34; 27.27; and 29.65.
- 53. (Currently amended) The crystalline hydrogen succinate salt of claim [[49,]]50 wherein the crystal form is characeterized by having is characterized by a DSC trace showing an endotherm with an onset at about 139-141°C.
- 54. (Currently amended) The <u>crystalline</u> malonate salt of claim 47, wherein the <u>malonate</u> salt is [[the]]a <u>crystalline</u> hydrogen malonate salt.
- 55. (Cancelled)
- 56. (Currently amended) The crystalline hydrogen malonate salt of claim [[55]]54, wherein the crystal form of the salt is characterized by an X-Ray powder diffractogram as shown in Figure 3.
- Currently amended) The crystalline hydrogen malonate salt of claim 56, wherein the X-Ray powder diffractogram, which was obtained using  $CuK_{\alpha 1}$  radiation ( $\lambda$ =1.5406 Å), showing-has characteristic peaks at the following 2θ-angles: 2θ-angles: 8.3; 10.6; 11.5; 12.8; 14.2; 14.5; 14.7; 15.8; 16.5; 17.4; 17.6; 18.0; 18.6; 19.2; 21.2; 22.0; 22.9; 23.7; 24.7; and 28.8.
- 58. (Currently amended) A pharmaceutical composition comprising the <u>crystalline succinate</u> salt or the <u>crystalline malonate</u> salt of claim 47 and at least one pharmaceutically acceptable carrier, filler or diluent.
- (Currently amended) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the crystalline succinate salt or the crystalline malonate salt of claim 47, wherein the disease or disorder is selected from the group consisting of a disorder exhibiting psychotic symptoms, a psychotic disorder, an anxiety disorder, an affective disorder, depression, schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar

Application Serial No. 10/568,572 (Attorney Docket No. 453-US-PCT) Response to Non-Final Office Action mailed: May 13, 2008 Dated: November 13, 2008

- disorder, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, and an abuse disorder.
- 60. (Cancelled)

Page 4 of 15

- 61. (Currently amended) The method of claim 59, wherein the disease or disorder is schizophrenia or a psychotic disorder Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder [[and]]or mania in bipolar disorder.
- 62. (Currently amended) The method of claim 61, wherein the schizophrenia comprises positive symptoms, negative symptoms, and/or-depressive symptoms, or a combination thereof.
- 63. (Currently amended) [[A]]The method of claim 59, treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the salt of claim 47, wherein the disease or disorder is selected from the group consisting of Schizophrenia,—Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.
- 64. (New) The method of claim 59, wherein the depression is depression in bipolar disorder.